{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-310764","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.473190+00:00","generated_at":"2026-05-16T14:01:56.967332+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cullinan Therapeutics reports 31% CR/CRh rate at 12 µg/kg for CLN-049 in R/R AML Phase 1","bullets":["At 12 µg/kg (n=16), CR/CRh rate 31% (5/16) and CRc rate 31% (5/16); at ≥6 µg/kg (n=32), CR/CRh 25% and CRc 28%.","In TP53-mutated AML patients at 12 µg/kg, 50% (4/8) achieved CR/CRh; 3 of 4 responses durable >16 weeks.","63% (5/8) of responders at ≥6 µg/kg had response >16 weeks; 2 patients proceeded to transplant.","Safety: CRS mostly Grade 1/2 (35.6%), no Grade 3 with two step-up doses; no discontinuations due to CRS.","FDA granted Fast Track designation; dose escalation continues with expansion cohorts planned early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-310764","json":"https://secwatch.observer/filing/0001193125-25-310764.json","markdown":"https://secwatch.observer/filing/0001193125-25-310764.md","text":"https://secwatch.observer/filing/0001193125-25-310764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312525310764/0001193125-25-310764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312525310764/cgem-20251208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:01:56.967332+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}